Immune Checkpoint Inhibitor Therapy and Cardiovascular Adverse Events
Five Year Outcomes with First Line OPDIVO® plus YERVOY® and a Limited Course of Chemotherapy
Late Breaking Abstract – ASCO 2024: Sustained Improvement in Relapse Free Survival with Personalized mRNA Cancer Vaccine plus KEYTRUDA® in Resected High Risk Melanoma
FDA Approves Bispecific T-Cell Engager IMDELLTRA® for Small Cell Lung Cancer
FDA Approves BREYANZI® for Relapsed/Refractory Follicular Lymphoma
Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric and GEJ Cancer Regardless of PD-L1 Status
Benefits of Neoadjuvant Chemoimmunotherapy in Early Stage Non Small Cell Lung Cancer
Cardiovascular Adverse Events Associated with Bispecific T-cell Engager Therapy
FDA Approves BREYANZI®, First CAR-T Cell Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves TEVIMBRA® for Advanced Esophageal Squamous Cell Carcinoma
Circulating Tumor DNA Can be Used as an Early Marker of Immunotherapy Response
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Adjuvant KEYTRUDA® Improves Overall Survival in Renal cell Carcinoma
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Subcutaneous Nivolumab Offers Efficiency and Efficacy in Renal Cell Carcinoma
FDA Approves KEYTRUDA® with Chemotherapy for HER2-Negative Gastric or GE Junction Adenocarcinoma
FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer
Late Breaking Abstract – ESMO Congress 2023: Perioperative OPDIVO® Plus Chemotherapy Improves Survival in Resectable Non Small Cell Lung Cancer
FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
KEYTRUDA® in Combination with HER2 Blockade Improves PFS in Gastric and GE Junction Cancer
FDA Approves Perioperative KEYTRUDA® for Resectable Early Stage Non Small Cell Lung Cancer
Adjuvant KEYTRUDA® in Resected NSCLC Irrespective of PD-L1 Expression
Bottom Ad
Advertisement
Subscribe
